CliffBio
small molecule

APTIOM

ESLICARBAZEPINE ACETATE

Loss of exclusivityAugust 2032latest FDA-listed patent expiry
CompanySumitomo Pharma America →See this company's full patent-cliff portfolio

Drug detail

Brand nameAPTIOM
Active ingredientESLICARBAZEPINE ACETATE
Strength400MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2013
Marketing statusRX

Listed patents

PatentExpiresType
9750747August 2032use U-2041
8372431April 2030product
9566244October 2028product
10912781October 2028product
9763954September 2028use U-2123
9643929April 2026product
9206135April 2026substance

More from Sumitomo Pharma America

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Not found